600 related articles for article (PubMed ID: 18760752)
1. Anemia and cardiovascular risk in the patient with kidney disease.
Fishbane S
Heart Fail Clin; 2008 Oct; 4(4):401-10. PubMed ID: 18760752
[TBL] [Abstract][Full Text] [Related]
2. Erythropoiesis-stimulating agents, hypertension and left ventricular hypertrophy in the chronic kidney disease patient.
Schmid H; Schiffl H; Lederer SR
Curr Opin Nephrol Hypertens; 2011 Sep; 20(5):465-70. PubMed ID: 21738032
[TBL] [Abstract][Full Text] [Related]
3. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
Singh AK
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
[TBL] [Abstract][Full Text] [Related]
4. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
5. [Treatment anaemia of chronic kidney disease in predialysis patients (stage 1-4)].
Lovcić V; Vujić J; Ivanac Janković R; Basić-Jukić N; Barisić I; Lovcić P; Dzapo M
Acta Med Croatica; 2009 Sep; 63 Suppl 1():11-6. PubMed ID: 20232547
[TBL] [Abstract][Full Text] [Related]
6. Hemoglobin levels, cardiovascular disease, and left ventricular hypertrophy in patients with chronic kidney disease. Case study of the anemic patient.
Butler KG
Nephrol Nurs J; 2002 Apr; 29(2):189-92. PubMed ID: 11997954
[TBL] [Abstract][Full Text] [Related]
7. Therapy with erythropoiesis-stimulating agents and renal and nonrenal outcomes.
Agarwal AK; Singh AK
Heart Fail Clin; 2010 Jul; 6(3):323-32. PubMed ID: 20630407
[TBL] [Abstract][Full Text] [Related]
8. [Anemia as a risk factor for CKD and CVD].
Tsuruya K; Hirakata H
Nihon Rinsho; 2008 Sep; 66(9):1786-93. PubMed ID: 18788410
[TBL] [Abstract][Full Text] [Related]
9. [Anemia in chronic kidney disease and its cardiovascular implications].
Cases A; Coll E; Collado S
Med Clin (Barc); 2009 May; 132 Suppl 1():38-42. PubMed ID: 19460479
[TBL] [Abstract][Full Text] [Related]
10. [Erythropoesis-stimulating agents: past, present and future].
Kes P; Basić-Jukić N
Acta Med Croatica; 2009 Sep; 63 Suppl 1():3-6. PubMed ID: 20235351
[TBL] [Abstract][Full Text] [Related]
11. [Role of renal anemia in progression of chronic kidney disease].
Racki S; Maleta I
Acta Med Croatica; 2009 Sep; 63 Suppl 1():33-7. PubMed ID: 20235353
[TBL] [Abstract][Full Text] [Related]
12. Peginesatide: a potential erythropoiesis stimulating agent for the treatment of anemia of chronic renal failure.
Doss S; Schiller B
Nephrol Nurs J; 2010; 37(6):617-26. PubMed ID: 21290916
[TBL] [Abstract][Full Text] [Related]
13. Anemia and the heart in chronic kidney disease.
Zalunardo N; Levin A
Semin Nephrol; 2006 Jul; 26(4):290-5. PubMed ID: 16949467
[TBL] [Abstract][Full Text] [Related]
14. [Regarding the optimal hemoglobin target range in renal anemia].
Maurin N
Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
[TBL] [Abstract][Full Text] [Related]
15. [Left ventricular hypertrophy in chronic kidney disease].
Paoletti E; Cannella G
G Ital Nefrol; 2006; 23(6):560-8. PubMed ID: 17173262
[TBL] [Abstract][Full Text] [Related]
16. Individualizing decision-making--resurrecting the doctor-patient relationship in the anemia debate.
Agarwal R
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1340-6. PubMed ID: 20448071
[TBL] [Abstract][Full Text] [Related]
17. Anemia in renal disease: diagnosis and management.
Lankhorst CE; Wish JB
Blood Rev; 2010 Jan; 24(1):39-47. PubMed ID: 19833421
[TBL] [Abstract][Full Text] [Related]
18. Piecing together the evidence on anemia: the link between chronic kidney disease and cardiovascular disease.
McCullough PA; Lepor NE
Rev Cardiovasc Med; 2005; 6 Suppl 3():S4-12. PubMed ID: 16340933
[TBL] [Abstract][Full Text] [Related]
19. Advancing chronic kidney disease care: new imperatives for recognition and intervention.
Szromba C; Thies MA; Ossman SS
Nephrol Nurs J; 2002 Dec; 29(6):547-59; quiz 560-1. PubMed ID: 12596604
[TBL] [Abstract][Full Text] [Related]
20. Evolving regulatory landscape with erythropoiesis-stimulating agents and impact on managed care.
Fatodu H
Am J Manag Care; 2010 Mar; 16 Suppl Issues():S74-9. PubMed ID: 20297875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
